8 ms·

Out of curiosity, did you actually see any pharma ads on OpenEvidence?

amber_raza 9mo ago
Great question. I haven't seen banner ads on OpenEvidence yet, but the 'hidden tax' of free tools is often Publisher Bias. Users have noted that some current tools heavily overweight citations from 'Partner Journals' (like NEJM/JAMA) because they index the full text, effectively burying better papers from non-partner journals in the vector retrieval. My goal is strictly Neutral Retrieval. By hitting the PubMed/OpenAlex APIs live, Evidex treats a niche pediatric journal with the same relevance weight as a major publisher, ensuring the 'Long Tail' of evidence isn't drowned out by business partnerships.
breadislove 9mo ago
this might be interesting: https://www.theinformation.com/articles/chatgpt-doctors-startup-doubles-valuation-12-billion-revenue-surges https://www.theinformation.com/articles/chatgpt-doctors-star... > $150M RR on just ads, +3x from August. On <1M users. source: https://x.com/ArfurRock/status/1999618200024076620 https://x.com/ArfurRock/status/1999618200024076620
- amber_raza 9mo ago
  Whoa. $150M ARR on ads is a wild stat. Thanks for sharing that source. It really validates the thesis that unless the user pays (SaaS), the Pharma companies are the real customers.
  - eoravkin 9mo ago
    You built a cool product. I'm actually one of the founders of https://medisearch.io https://medisearch.io which is similar to what you are building. I think the long-tail problem that you describe can be solved in other ways than with live APIs and you may find other problems with using live APIs.
    - amber_raza 9mo ago
      Thanks! I just took a look at MediSearch. It looks really clean. You are definitely right that Live APIs come with their own headaches (mostly latency and rate limits). For now, I chose this path to avoid the infrastructure overhead of maintaining a massive fresh index as a solo dev. However, I suspect that as usage grows, I will have to move toward a hybrid model where I cache or index the 'head' of the query distribution to improve performance. Always great to meet others tackling this space. I’d love to swap notes sometime if you are open to it.

Great question. I haven't seen banner ads on OpenEvidence yet, but the 'hidden tax' of free tools is often Publisher Bias. Users have noted that some current tools heavily overweight citations from 'Partner Journals' (like NEJM/JAMA) because they index the full text, effectively burying better papers from non-partner journals in the vector retrieval. My goal is strictly Neutral Retrieval. By hitting the PubMed/OpenAlex APIs live, Evidex treats a niche pediatric journal with the same relevance weight as a major publisher, ensuring the 'Long Tail' of evidence isn't drowned out by business partnerships.

breadislove 9mo ago

this might be interesting: https://www.theinformation.com/articles/chatgpt-doctors-startup-doubles-valuation-12-billion-revenue-surges https://www.theinformation.com/articles/chatgpt-doctors-star... > $150M RR on just ads, +3x from August. On <1M users. source: https://x.com/ArfurRock/status/1999618200024076620 https://x.com/ArfurRock/status/1999618200024076620

amber_raza 9mo ago
Whoa. $150M ARR on ads is a wild stat. Thanks for sharing that source. It really validates the thesis that unless the user pays (SaaS), the Pharma companies are the real customers.
- eoravkin 9mo ago
  You built a cool product. I'm actually one of the founders of https://medisearch.io https://medisearch.io which is similar to what you are building. I think the long-tail problem that you describe can be solved in other ways than with live APIs and you may find other problems with using live APIs.
  - amber_raza 9mo ago
    Thanks! I just took a look at MediSearch. It looks really clean. You are definitely right that Live APIs come with their own headaches (mostly latency and rate limits). For now, I chose this path to avoid the infrastructure overhead of maintaining a massive fresh index as a solo dev. However, I suspect that as usage grows, I will have to move toward a hybrid model where I cache or index the 'head' of the query distribution to improve performance. Always great to meet others tackling this space. I’d love to swap notes sometime if you are open to it.